Cargando…
Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma
BACKGROUND: The purpose of this systematic review is to summarize and evaluate the available published data regarding the efficacy and safety of a combination product containing fluticasone propionate/formoterol (FP-F) in order to establish its potential role compared with other inhaled combination...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459636/ https://www.ncbi.nlm.nih.gov/pubmed/26082638 http://dx.doi.org/10.2147/TCRM.S55116 |
_version_ | 1782375250416107520 |
---|---|
author | Prosser, Theresa R Bollmeier, Suzanne G |
author_facet | Prosser, Theresa R Bollmeier, Suzanne G |
author_sort | Prosser, Theresa R |
collection | PubMed |
description | BACKGROUND: The purpose of this systematic review is to summarize and evaluate the available published data regarding the efficacy and safety of a combination product containing fluticasone propionate/formoterol (FP-F) in order to establish its potential role compared with other inhaled combination corticosteroid/long-acting beta(2) receptor agonists for the maintenance treatment of asthma. METHODS: A PubMed and EMBASE search was conducted using the terms “fluticasone propionate”, “formoterol fumarate”, “Flutiform(®)”, and “asthma” in July 2014 to identify trials using this combination specifically for the treatment of asthma. Additional information was gathered from references cited in the identified publications, the package insert, and the ClinicalTrials. gov registry. All randomized controlled clinical trials for humans in asthma were evaluated for inclusion. Data from animal trials, clinical trials for chronic obstructive pulmonary disease, and non-English sources were excluded. RESULTS: Seven short-term safety and efficacy trials of FP-F compared with its individual components and two comparison trials of FP-F versus other combination products were identified. Generally, the incidence of drug-related adverse events was low and consistent with previously reported drug class-related adverse events (ie, pharyngitis, dysphonia, and headache). The combination of FP-F was shown to be noninferior to fluticasone propionate/salmeterol for improving predose forced expiratory volume at one second (FEV(1)) and 2 hours post dose FEV(1). FP-F was also noninferior to budesonide/formoterol in improving predose FEV(1). Other clinical endpoints, including various symptom scores, asthma control, quality of life, and subjects’ assessment of the medications were not significantly different. CONCLUSION: Poor asthma control is common. The data from short-term studies indicate that this inhaled corticosteroid and long-acting beta(2) receptor agonist combination product is non-inferior to similar combination products available. As FP-F is available in different strengths, the corticosteroid dose can be titrated without changing devices. A potential advantage is that those with good technique, the same type of device could be used for both their controller and rapid relief inhaler medicines. The choice of this combination versus other similar products may be based primarily on cost. |
format | Online Article Text |
id | pubmed-4459636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44596362015-06-16 Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma Prosser, Theresa R Bollmeier, Suzanne G Ther Clin Risk Manag Review BACKGROUND: The purpose of this systematic review is to summarize and evaluate the available published data regarding the efficacy and safety of a combination product containing fluticasone propionate/formoterol (FP-F) in order to establish its potential role compared with other inhaled combination corticosteroid/long-acting beta(2) receptor agonists for the maintenance treatment of asthma. METHODS: A PubMed and EMBASE search was conducted using the terms “fluticasone propionate”, “formoterol fumarate”, “Flutiform(®)”, and “asthma” in July 2014 to identify trials using this combination specifically for the treatment of asthma. Additional information was gathered from references cited in the identified publications, the package insert, and the ClinicalTrials. gov registry. All randomized controlled clinical trials for humans in asthma were evaluated for inclusion. Data from animal trials, clinical trials for chronic obstructive pulmonary disease, and non-English sources were excluded. RESULTS: Seven short-term safety and efficacy trials of FP-F compared with its individual components and two comparison trials of FP-F versus other combination products were identified. Generally, the incidence of drug-related adverse events was low and consistent with previously reported drug class-related adverse events (ie, pharyngitis, dysphonia, and headache). The combination of FP-F was shown to be noninferior to fluticasone propionate/salmeterol for improving predose forced expiratory volume at one second (FEV(1)) and 2 hours post dose FEV(1). FP-F was also noninferior to budesonide/formoterol in improving predose FEV(1). Other clinical endpoints, including various symptom scores, asthma control, quality of life, and subjects’ assessment of the medications were not significantly different. CONCLUSION: Poor asthma control is common. The data from short-term studies indicate that this inhaled corticosteroid and long-acting beta(2) receptor agonist combination product is non-inferior to similar combination products available. As FP-F is available in different strengths, the corticosteroid dose can be titrated without changing devices. A potential advantage is that those with good technique, the same type of device could be used for both their controller and rapid relief inhaler medicines. The choice of this combination versus other similar products may be based primarily on cost. Dove Medical Press 2015-06-02 /pmc/articles/PMC4459636/ /pubmed/26082638 http://dx.doi.org/10.2147/TCRM.S55116 Text en © 2015 Prosser and Bollmeier. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review Prosser, Theresa R Bollmeier, Suzanne G Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma |
title | Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma |
title_full | Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma |
title_fullStr | Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma |
title_full_unstemmed | Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma |
title_short | Fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma |
title_sort | fluticasone-formoterol: a systematic review of its potential role in the treatment of asthma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459636/ https://www.ncbi.nlm.nih.gov/pubmed/26082638 http://dx.doi.org/10.2147/TCRM.S55116 |
work_keys_str_mv | AT prossertheresar fluticasoneformoterolasystematicreviewofitspotentialroleinthetreatmentofasthma AT bollmeiersuzanneg fluticasoneformoterolasystematicreviewofitspotentialroleinthetreatmentofasthma |